NASDAQ:ACHV - Achieve Life Sciences Stock Price, News, & Analysis

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Shares of Achieve Life Sciences reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.

Achieve Life Sciences Inc (NASDAQ:ACHV) issued its earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.18. View Achieve Life Sciences' Earnings History.

Achieve Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Achieve Life Sciences.

1 brokers have issued 12 month target prices for Achieve Life Sciences' shares. Their predictions range from $12.00 to $12.00. On average, they expect Achieve Life Sciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 307.8% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.

News headlines about ACHV stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achieve Life Sciences earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the next several days.

Some companies that are related to Achieve Life Sciences include Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), ImmuCell (ICCC), GeneNews (GNWSF), Akers Biosciences (AKER), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Synergy Pharmaceuticals (SGYP), SLS International (SLS), Novavax (NVAX), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Celldex Therapeutics (CLDX), Sangamo Therapeutics (SGMO), Arena Pharmaceuticals (ARNA), Verastem (VSTM) and Amicus Therapeutics (FOLD).

Achieve Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Worth Venture Partners LLC (1.33%). View Institutional Ownership Trends for Achieve Life Sciences.

ACHV stock was purchased by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC. View Insider Buying and Selling for Achieve Life Sciences.

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ACHV stock can currently be purchased for approximately $2.9425.

Achieve Life Sciences has a market capitalization of $19.77 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-12,690,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis.

The official website for Achieve Life Sciences is achievelifesciences.com.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]